The rationale of the study was to formulate orodispersible tablets of Valsartan for improving its poor oral bioavailability and with the aim of alleviating administration to patients facing problems with swallowing. Drug and excipients were characterized by infrared spectroscopy and differential scanning calorimetry. Valsartan tablets were formulated by using mannitol, methyl carboxy cellulose, croscarmellose sodium, crospovidone, sodium starch glycolate, aspartame, sodium bicarbonate, and citric acid and magnesium stearate. The formulations were characterized for their physical properties, weight variation, disintegration time, binding efficiency, wetting properties, content uniformity, and in-vitro dissolution. F1 showed the disintegration time of 20 sec and in-vitro drug release 93.43% within 20 min. The similarity factor (ƒ2) is found to be 52.74 for the F1 formulation in which the release is greater to that of the marketed product (Diovan). The promising formulation (F1) was found to be stable during the stability studies conducted as per ICH guidelines, as it showed no significant changes in the physicochemical properties, disintegration time and in-vitro drug release.
